Solid Biosciences Q1 net loss widens on higher R&D costs

Solid Biosciences

12/05/2026 21:23

Overview

US genetic medicines developer's Q1 net loss widened yr/yr on higher R&D expenses

Company ended Q1 with $380.7 mln in cash, expects runway into H1 2028

First participant dosed in Phase 3 Duchenne trial; progress in early-stage pipeline programs

Outlook

Company expects cash runway to extend into H1 2028

Solid anticipates initial data from SGT-212 trial by year-end 2026, subject to enrollment

Result Drivers

R&D SPENDING - Higher research and development costs, mainly for SGT-003 manufacturing and clinical activities, drove increased expenses

PIPELINE PROGRESS - Initiation of Phase 3 IMPACT DUCHENNE trial and continued dosing in Phase 1/2 INSPIRE DUCHENNE trial contributed to higher costs

PERSONNEL AND SUPPORT COSTS - Increased personnel and consulting expenses added to operating costs

Company press release: ID:nGNXb6zc99

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$56.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Solid Biosciences Inc is $16.50, about 114.8% above its May 11 closing price of $7.68

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)